Kleineidam, Luca
,
Chouraki, Vincent
Próchnicki, Tomasz
van der Lee, Sven J.
Madrid-Márquez, Laura
Wagner-Thelen, Holger
Karaca, Ilker
Weinhold, Leonie
Wolfsgruber, Steffen
Boland, Anne
Martino Adami, Pamela V.
Lewczuk, Piotr
Popp, Julius
Brosseron, Frederic
Jansen, Iris E.
Hulsman, Marc
Kornhuber, Johannes
Peters, Oliver
Berr, Claudine
Heun, Reinhard
Frölich, Lutz
Tzourio, Christophe
Dartigues, Jean-François
Hüll, Michael
Espinosa, Ana
Hernández, Isabel
de Rojas, Itziar
Orellana, Adelina
Valero, Sergi
Stringa, Najada
van Schoor, Natasja M.
Huisman, Martijn
Scheltens, Philip
Rüther, Eckart
Deleuze, Jean-Francois
Wiltfang, Jens
Tarraga, Lluis
Schmid, Matthias
Scherer, Martin
Riedel-Heller, Steffi
Heneka, Michael T.
Amouyel, Philippe
Jessen, Frank
Boada, Merce
Maier, Wolfgang
Schneider, Anja
González-Pérez, Antonio
van der Flier, Wiesje M.
Wagner, Michael
Lambert, Jean-Charles
Holstege, Henne
Sáez, Mª Eugenia
Latz, Eicke
Ruiz, Agustin
Ramirez, Alfredo http://orcid.org/0000-0003-4991-763X
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01GI0102, 01GI0420, 01GI0422, 01GI0423, 01GI0429, 01GI0431, 01GI0433, 01GI0434, 01GI0710, 01GI0711, 01GI0712, 01GI0713, 01GI0714, 01GI0715, 01GI0716, 01ET1006B, 01EA1410A, 01ED1619A)
Bundesministerium für Bildung und Forschung (01GI0420, 01GI0422)
Bundesministerium für Bildung und Forschung (01GI0433)
Deutsche Forschungsgemeinschaft (RA 1971/6-1)
ZonMw (733051061)
Innovative Medicines Initiative (115975, 115372)
Instituto de Salud Carlos III (PI13/02434)
Instituto de Salud Carlos III (PI16/01861, PI19/01301)
Netherlands Organization for Scientific Research (480-10-014)
Swiss National Science Foundation (320030L_141179)
Article History
Received: 9 November 2019
Revised: 19 February 2020
Accepted: 20 February 2020
First Online: 12 March 2020
Compliance with ethical standards
:
: All authors report no conflict of interest. Piotr Lewczuk received a consultation and/or lecture honoraria from IBL International, Fujirebio Europe, AJ Roboscreen, and Roche. Jens Wiltfang received honoraria for consulting activities, lectures or advisory board participation from Pfizer, Eli Lilly, Hoffmann-La-Roche, MSD Sharp + Dome, Janssen-Cilag GmbH, Immungenetics AG, Boehringer Ingelheim. Lutz Frölich received honoraria for consulting activities, lectures, or advisory board participation from Allergan, Eli Lilly, Avraham Pharmaceuticals, Axon Neuroscience, Axovant, Biogen, Boehringer Ingelheim, Eisai, Functional Neuromodulation, Lundbeck, MerckSharpe and Dohme, Novartis, Pfizer, Pharnext, Roche, Schwabe Pharma; he served on Data and Safety Monitoring boards or endpoint committees with Avraham Pharmaceuticals, Axon Neuroscience, Forschungszentrum Jülich, Novartis, Pharmatropix. Julius Popp received honoraria for consulting activities, lectures or advisory board participation from Fujirebio Europe, Ono Pharma, Eli Lilly, and Nestlé Institute of Health Sciences. Agustin Ruiz reports consulting Fees: Landsteiner Genmed, Grifols, Araclon biotech. And Lecture Fees: Araclon Biotech.PA reports personal fees from Servier, Total, Genoscreen, Takeda, and Foundation Alzheimer. Oliver Peters received research funding, consultancy fees, or speech honoraria from Axovant, Biogen, Genentech, Lilly, Lundbeck, Novartis, Pharmatrophix, Piramal, Probiodrug, Roche, Takeda, and TauRx Pharmaceuticals. Merce Boada receives fees or has received for consulting from Lab. Servier, Roche, Lilly, Avid, Bayer, Elan, Janssen, Neuroptix, and Sanofi. She receives or has received fees for lectures from Lilly, Nutricia, Roche, Schwabe, Araclon, Esteve, Grifols, Janssen, Novartis, Piramal, Pfizer-Wyett, and Servier. She receives fees for being part of the Advisory Board of Lilly and Schwabe. She reports grants/research funding from Abbvie, Araclon, Biogen Research Limited, Bioiberica, Grifols, Lilly, S.A, Merck Sharp and Dohme, Kyowa Hakko Kirin, Laboratorios Servier, Nutricia SRL, Oryzon Genomics, Piramal Imaging Limited, Roche Pharma SA, and Schwabe Farma iberica SLU, all outside the submitted work. She has not received personal compensations from these organizations.
: All procedures performed in studies involving human participants were following the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this retrospective study, all patients’ clinical, genetic, and biomarker data were already available at the time point of this study.